• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Madrigal Pharmaceuticals Inc.

    9/11/25 4:30:55 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDGL alert in real time by email
    S-8 1 tm2525766d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on September 11, 2025

    Registration No. 333-  

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

     

    MADRIGAL PHARMACEUTICALS, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware   04-3508648
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    Four Tower Bridge
    200 Barr Harbor Drive, Suite 200
    West Conshohocken, Pennsylvania 19428
    (Address of Principal Executive Offices, Zip Code)

     

    MADRIGAL PHARMACEUTICALS, INC. 2025 INDUCEMENT STOCK PLAN, AS AMENDED

    (Full title of the plan)

     

    Mardi Dier

    Executive Vice President and Chief Financial Officer

    Madrigal Pharmaceuticals, Inc.

    Four Tower Bridge

    200 Barr Harbor Drive, Suite 200

    West Conshohocken, Pennsylvania 19428

    (Name and address of agent for service)

     

    (267) 824-2827

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Gregg Katz, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, MA 02210

    (617) 570-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
           
    Non-accelerated filer ¨ Smaller reporting company ¨
           
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E to Form S-8, this Registration Statement on Form S-8 (the “Registration Statement”) is being filed by Madrigal Pharmaceuticals, Inc. (the “Registrant”) to register an additional 300,000 shares of common stock, par value $0.0001 per share (the “Common Stock”), reserved and available for issuance under the 2025 Inducement Stock Plan (the “2025 Inducement Plan”) of the Registrant, as amended.

     

    On June 16, 2025, the Board of Directors of the Registrant (the “Board”) adopted the 2025 Inducement Plan. The 2025 Inducement Plan was adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4) and is administered by the Compensation Committee of the Board. On September 11, 2025, the Board adopted the Amendment No. 1 to the 2025 Inducement Plan, which increased the number of shares reserved and available for issuance under the 2025 Inducement Plan by 300,000 shares of Common Stock. Amendment No. 1 was adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4).

     

    The only persons eligible to receive grants of Inducement Awards (as defined below) under the 2025 Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Listing Rule 5635(c)(4). An “Inducement Award” means any right to receive the Registrant’s common stock, cash or other property granted under the 2025 Inducement Plan (including nonqualified stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards or other stock-based awards).

     

    This Registration Statement registers additional securities of the same class as other securities of the Registrant for which the registration statement filed on Form S-8 relating to the 2025 Inducement Plan (File No. 333-288200) of the Registrant is effective. The information contained in the Registrant’s registration statement on Form S-8 relating to the 2025 Inducement Plan (File No. 333-288200) is hereby incorporated by reference pursuant to General Instruction E of Form S-8, except with respect to Item 8. Exhibits thereof.

     

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.  

     

    The exhibits listed on the Exhibit Index immediately preceding such exhibits are filed as part of this Registration Statement, and the contents of the Exhibit Index are incorporated herein by reference.

     

    EXHIBIT INDEX

     

                Incorporated by Reference
    Exhibit 
    Number
      Exhibit Description   Filed
    Herewith
      Form   SEC File /
    Registration Number
      Exhibit   Filing Date
    4.1   Restated Certificate of Incorporation of the Registrant       10-K   001-33277   3.1   03/31/17
                             
    4.2   Certificate of Amendment to Restated Certificate of Incorporation of the Registrant       8-K   001-33277   3.1   06/20/23
                             
    4.3   Restated Bylaws of the Registrant        8-K   001-33277   3.1   04/14/16
                             
    5.1   Opinion of Goodwin Procter LLP   X                
                           
    23.1   Consent of Goodwin Procter LLP (included in opinion of counsel filed as Exhibit 5.1)   X                
                           
    23.2   Consent of PricewaterhouseCoopers LLP   X                
                           
    24   Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement)   X                
                           
    99.1   2025 Inducement Plan       S-8   333-288200   99.1   06/20/25
                             
    99.2   Form of Non-Qualified Stock Option Agreement       S-8   333-288200   99.2   06/20/25
                             
    99.3   Form of Restricted Stock Unit Award Agreement (Non-Section 16 Officers)       S-8   333-288200   99.3   06/20/25
                             
    99.4   Form of Restricted Stock Unit Award Agreement (Section 16 Officers)       S-8   333-288200   99.4   06/20/25
                             
    99.5   Form of Performance-Based Restricted Stock Unit Award Agreement       S-8   333-288200   99.5   06/20/25
                             
    99.6   Amendment No. 1 to the 2025 Inducement Plan   X                
                             
    107   Filing Fee table   X                

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in West Conshohocken, Pennsylvania, on September 11, 2025.

     

      MADRIGAL PHARMACEUTICALS, INC.
         
      By: /s/ William J. Sibold
        William J. Sibold
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints William J. Sibold and Mardi Dier, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement of Madrigal Pharmaceuticals, Inc. and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name   Title   Date
             
    /s/ William J. Sibold   President and Chief Executive Officer and Director   September 11, 2025
    William J. Sibold   (Principal Executive Officer)    
             
    /s/ Mardi C. Dier   Chief Financial Officer   September 11, 2025
    Mardi C. Dier   (Principal Financial and Accounting Officer)    
             
    /s/ Julian C. Baker   Chairman of the Board   September 11, 2025
    Julian C. Baker        
             
    /s/ Kenneth M. Bate   Director   September 11, 2025
    Kenneth M. Bate        
             
    /s/ Raymond Cheong, M.D., Ph.D.   Director   September 11, 2025
    Raymond Cheong, M.D., Ph.D.        
             
    /s/ Daniel Brennan   Director   September 11, 2025
    Daniel Brennan        
             
    /s/ James M. Daly   Director   September 11, 2025
    James M. Daly        
             
    /s/ Paul A. Friedman, M.D.   Director   September 11, 2025
    Paul A. Friedman, M.D.        
             
    /s/ Jacqualyn A. Fouse, Ph.D.   Director   September 11, 2025
    Jacqualyn A. Fouse, Ph.D.        
             
    /s/ Richard S. Levy, M.D.   Director   September 11, 2025
    Richard S. Levy, M.D.        
             
    /s/ Rebecca Taub, M.D.   Senior Scientific and Medical Advisor and Director   September 11, 2025
    Rebecca Taub, M.D.        

     

     

    Get the next $MDGL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDGL

    DatePrice TargetRatingAnalyst
    9/4/2025$500.00Buy
    H.C. Wainwright
    2/28/2025$236.00 → $422.00Neutral → Buy
    B. Riley Securities
    2/27/2025$400.00 → $405.00Buy
    H.C. Wainwright
    6/28/2024Neutral
    Cantor Fitzgerald
    6/11/2024$382.00Outperform
    Wolfe Research
    4/22/2024$150.00Underperform
    BofA Securities
    3/15/2024$155.00 → $270.00Sell → Neutral
    B. Riley Securities
    3/6/2024$382.00Buy
    Citigroup
    More analyst ratings

    $MDGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

    CONSHOHOCKEN, Pa., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 15, 2025 to 76 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as inducement material to employees' acceptance of employment with the company. The new employees received, in the aggrega

    9/18/25 4:05:00 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

    CONSHOHOCKEN, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 1, 2025 to 17 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as inducement material to employees' acceptance of employment with the company. The new employees received, in the aggregat

    9/4/25 4:05:00 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

    CONSHOHOCKEN, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that the company will participate in the Morgan Stanley 23rd Annual Global Health Care Conference on Monday, Sept. 8, 2025 at 7:45 A.M. EDT. The presentation will be webcast live and may be accessed here or by visiting Madrigal's Investor Relations Events and Presentations page. A replay of the webcast will be available after the event. About MadrigalMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madr

    9/3/25 8:00:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Sibold William John sold $3,243,741 worth of shares (7,279 units at $445.63), decreasing direct ownership by 7% to 102,474 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    9/9/25 9:07:34 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Sibold William John sold $3,047,756 worth of shares (7,616 units at $400.18), decreasing direct ownership by 6% to 109,753 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    8/21/25 5:44:27 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Bros. Advisors Lp bought $36,941,197 worth of shares (97,065 units at $380.58) (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    8/20/25 6:12:22 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Madrigal Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Madrigal Pharmaceuticals with a rating of Buy and set a new price target of $500.00

    9/4/25 9:01:44 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals upgraded by B. Riley Securities with a new price target

    B. Riley Securities upgraded Madrigal Pharmaceuticals from Neutral to Buy and set a new price target of $422.00 from $236.00 previously

    2/28/25 8:25:11 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Madrigal Pharmaceuticals with a new price target

    H.C. Wainwright reiterated coverage of Madrigal Pharmaceuticals with a rating of Buy and set a new price target of $405.00 from $400.00 previously

    2/27/25 6:40:20 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baker Bros. Advisors Lp bought $36,941,197 worth of shares (97,065 units at $380.58) (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    8/20/25 6:12:22 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Bros. Advisors Lp bought $24,979,827 worth of shares (68,618 units at $364.04) (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    8/20/25 6:09:53 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Baker Bros. Advisors Lp bought $22,516,577 worth of shares (101,792 units at $221.20) (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    12/14/23 6:10:59 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REZDIFFRA issued to MADRIGAL PHARMACEUTICALS INC

    Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity

    3/14/24 3:35:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDGL
    SEC Filings

    View All

    SEC Form S-8 filed by Madrigal Pharmaceuticals Inc.

    S-8 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)

    9/11/25 4:30:55 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Madrigal Pharmaceuticals Inc.

    144 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    8/29/25 4:06:09 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Madrigal Pharmaceuticals Inc.

    144 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    8/20/25 4:12:31 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDGL
    Financials

    Live finance-specific insights

    View All

    Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates

    Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, 2045Announced global licensing agreement for an oral GLP-1 development candidate In July, secured up to $500 million in senior secured credit to advance pipeline Presented compelling two-year F4c data at EASL Congress; provides estimates for U.S. F4c MASH patient population Received positive CHMP opinion recommending approval of Rezdiffra for the treatment of MASH in EuropeAppointed Dan Brennan to Board of Directors Reports cash, cash equivalents, restricted cash and marketable securities of $802.

    8/5/25 7:00:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

    First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10)Appointed David Soergel, M.D., to Chief Medical Officer; Rebecca Taub, M.D., named Senior Scientific and Medical Advisor Appointed Jacqualyn Fouse, Ph.D., to Board of DirectorsReports cash, cash equivalents, restricted cash and marketable securities of $848.1 million at March 31, 2025Company to host conference call today, May 1, 2025, at 8 a.m. EDT CONSHOHOCKEN, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc.

    5/1/25 7:00:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

    Patients achieved a mean 6.7 kPa reduction in liver stiffness as measured by vibration-controlled transient elastography (VCTE); this represents the largest reduction in liver stiffness reported in a compensated MASH cirrhosis patient population 51% of patients achieved a ≥25% reduction in liver stiffness; a reduction of this magnitude has been associated with reduced progression to end-stage liver diseaseCompany to review topline data during its fourth-quarter and full-year 2024 financial results conference call today, February 26, 2025, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused

    2/26/25 6:30:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Madrigal Pharmaceuticals Inc.

    SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    11/14/24 5:18:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Madrigal Pharmaceuticals Inc.

    SC 13G - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    11/14/24 6:30:21 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Madrigal Pharmaceuticals Inc. (Amendment)

    SC 13D/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    3/25/24 4:28:21 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDGL
    Leadership Updates

    Live Leadership Updates

    View All

    Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

    Fred Craves, Ph.D. to retire from Madrigal's Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed Jacqualyn ("Jackie") Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025. Julian Baker, Chairman of the Board of Directors, stated, "I am delighted to welcome Jackie Fouse to Madrigal. Jackie is an accomplished biotech executive who brings more than 30 years of healthcare industry and finance experience

    3/11/25 8:00:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

    CONSHOHOCKEN, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced the appointment of Michael R. Charlton, M.B.B.S., F.R.C.P., as Senior Vice President, Clinical Development, effective October 1, 2024. Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal, stated, "I am thrilled to have Dr. Charlton joining the Madrigal team; his deep experience as a researcher and clinician treating patients with NASH will bring powerful new insights and ca

    10/1/24 8:00:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

    CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024. Bill Sibold, Chief Executive Officer of Madrigal, stated, "Shannon is an outstanding leader who brings a wealth of expertise to her new role as General Counsel. She joined the Madrigal team in 2024 as Chief Compliance Officer and played an instrumental role guiding the company through a period of rapid growth. I feel privileged to be working with Shannon and the other members of our leader

    8/2/24 7:00:21 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care